List view / Grid view
Researchers in Japan have developed long-lasting 3D liver organoids from stem cells by incorporating bile acids into the culture medium - offering a new model for studying chronic liver diseases.
Researchers at SR-TIGET in Milan have developed a novel gene therapy approach that supercharges CAR-T cell therapy against glioblastoma – strengthening treatment against one of the world’s deadliest brain cancers.
Scientists from Nagoya University have developed a fast and safe method to create lung cells from skin-like fibroblasts - without using stem cells. This technique could allow for new regenerative therapies for diseases like chronic obstructive pulmonary disease (COPD).
Researchers at the University of Basel and Roche have discovered that slowing the intracellular transport of RNA-based drugs significantly improves their therapeutic impact.
A new “leukaemia-on-a-chip” device replicates human bone marrow and immune interactions, enabling researchers to observe CAR T cell therapies in action - potentially allowing for more personalised treatment strategies for leukaemia patients.
A study from Weill Cornell Medicine shows that pre-treating pancreatic islet cells with a small molecule cocktail significantly improves survival after transplantation in type 1 diabetes models. The approach could help make donor cells go further and transplants more efficient.
Scientists have successfully grown liver organoids with fully functional blood vessels- potentially allowing for the development of new treatments for haemophilia and liver disease.
Researchers have developed a new method to generate CAR T cells directly inside the body using targeted lipid nanoparticles that deliver mRNA to T cells - offering a safer, faster and more accessible alternative to traditional cell therapies for cancer and autoimmune diseases.
Researchers at Washington University in St. Louis have received a $250,000 grant from the Critical Path Institute’s Translational Therapeutics Accelerator (TRxA) to develop a novel CD22 bidentate therapeutic for type 1 diabetes to support formulation and new preclinical studies.
Researchers at The University of Osaka have found how structural changes in the VP1 protein of AAV vectors trigger genome release - offering insights for improving the safety, efficiency and stability of gene therapy delivery systems.
Researchers have developed a novel gene therapy approach that reactivates dormant genes by repositioning them closer to genetic switches called enhancers - showing promise for treating blood disorders like sickle cell disease.
DenovAI has unveiled a powerful AI-driven protein design platform capable of creating new, functional synthetic proteins from scratch - marking a big step forward for drug discovery.
SynaptixBio has selected its lead drug candidate, SB H-19642, for clinical trials to treat H-ABC - a rare, fatal neurodegenerative disease with no current cure.
Stanford scientists have successfully grown heart and liver organoids that include functioning blood vessels. This breakthrough overcomes a major size and maturity barrier, which could advance disease modelling and regenerative therapies in the future.
Shift Bioscience has announced new aging research, highlighting the discovery of SB000. This novel single-gene target reverses cellular aging without activating dangerous pluripotency pathways.
